MedPath

Bilateral and Unilateral Amblyopia Treatment Study

Terminated
Conditions
Amblyopia
Interventions
Other: Prescription glasses for bilateral amblyopia
Other: Prescription glasses for unilateral amblyopia
Registration Number
NCT03780205
Lead Sponsor
Salus University
Brief Summary

The purpose for this study is to investigate spectacle compliance and treatment outcome in bilateral and unilateral refractive amblyopia in children age 3 to \<10 years old. Specifically, how frequently and for what duration is spectacle wear necessary to maximize best-corrected visual acuity by spectacle correction alone.

Detailed Description

The purpose for this study is to investigate spectacle compliance and treatment outcome in bilateral and unilateral refractive amblyopia in children age 3 to \<10 years old. Specifically, how frequently and for what duration is spectacle wear necessary to maximize best-corrected visual acuity by spectacle correction alone.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
1
Inclusion Criteria
  • Age 3 to < 10 years
  • Subjects and their parent/guardian speak and understand English adequately to complete the study protocol and give informed consent. Subjects have the ability to adhere to the study visit schedule.
  • All refractive error measures below will be determined by cycloplegic retinoscopy by one of the study investigators during the comprehensive eye exam. Measures are in minus cylinder spectacle prescription format.

Inclusion criteria for bilateral amblyopia:

The major eligibility criteria include:

  • Best-corrected visual acuity of <20/30 each eye.

  • For hypermetropia:

    • Spherical equivalent >+2.00 D each eye.
    • Spherical equivalent difference between eyes <1.25 D.
  • For astigmatism without hypermetropia criteria above or myopia criteria below:

    • >1.75 D each eye
    • Difference between eyes <1.25 D
  • For myopia:

    • Spherical equivalent <-5.00.
    • Spherical equivalent difference between eyes <1.25 D.

Inclusion criteria for unilateral amblyopia:

The major eligibility criteria include:

  • Presence of anisometropia or constant unilateral strabismus.

  • Best-corrected visual acuity in the amblyopic eye <20/30; and interocular difference of best-corrected visual acuity at least two logMAR lines.

  • For anisometropia:

    • Spherical equivalent ≥ 1.00 D interocular difference
    • Astigmatism >1.75 D interocular difference
  • For constant unilateral strabismus where spectacle prescription is indicated. Examples where spectacle prescription is indicated include esotropia caused at least in part by an accommodative component or where significant refractive error in either eye warrants spectacle prescription for improved vision.

Exclusion Criteria
  • History of spectacle wear
  • Previous treatment for amblyopia
  • Active amblyopia treatment planned other than spectacles at enrollment
  • Prior intraocular or refractive surgery
  • Ocular or systemic abnormalities that the examining investigator deems could impact prognosis for visual improvement. Examples could include birth history that may have affected brain development, extremely low birth weight (<1.5 lbs), seizure disorders, cerebral palsy, optic nerve hypoplasia, cranial nerve palsy. Examples that would usually not exclude are off axis media opacity, low birth weight (2.0-3.5 lbs) without complication, mild limitation of extraocular muscle. Cognitive impairment that prohibits accurate data collection

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Bilateral GroupPrescription glasses for bilateral amblyopiaPatients have bilateral amblyopia, which is defined that best-corrected visual acuity of \<20/30 each eye.
Unilateral GroupPrescription glasses for unilateral amblyopiaPatients have unilateral amblyopia, which is defined that best-corrected visual acuity of \<20/30 in the amblyopic eye; and interocular difference of best-corrected visual acuity at least two logMAR lines.
Primary Outcome Measures
NameTimeMethod
visual acuity change from the baseline8 weeks

visual acuity change from the baseline in logMAR

adherence with optical treatment8 weeks

The adherence recorded with the microsensor will be calculated as a percentage.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Salus University

🇺🇸

Elkins Park, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath